Opendata, web and dolomites

LEGACy SIGNED

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LEGACy project word cloud

Explore the words cloud of the LEGACy project. It provides you a very rough idea of what is the project "LEGACy" about.

respectively    omics    bacterium    genome    death    virus    rates    extended    medicine    molecular    revolutionized    gcs    epidemiology    723    men       primary    multiple    arrival    histological    highest    health    cancer    stage    sharp    strategies    countries    legacy    secondary    deaths    tumour    epstein    international    northern    dietary    integrative    ebv    similarly    conceptual    genetic    model    gc    prevention    pylori    personalized    populations    positive    outcomes    disease    epidemiological    poorly    mortality    lowest    locally    strategy    america    multicentre    barr    women    none    participating    databases    public    globally    prognosis    eastern    standpoint    asian    10    vary    central    makeup    biology    susceptibility    strains    levels    infection    helicobacter    asia    24    plays    differences    gastric    intervention    contrast    sexes    patients    south    treatments    location    worldwide    urgent    incidence    celac    total    largely   

Project "LEGACy" data sheet

The following table provides information about the project.

Coordinator
FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA 

Organization address
address: AV MENENDEZ PELAYO 4
city: VALENCIA
postcode: 46010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 3˙993˙056 €
 EC max contribution 3˙577˙431 € (90%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA ES (VALENCIA) coordinator 638˙315.00
2    IPATIMUP - INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP PT (PORTO) participant 660˙162.00
3    FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON ES (BARCELONA) participant 550˙000.00
4    STICHTING VUMC NL (AMSTERDAM) participant 471˙875.00
5    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 305˙235.00
6    ANAXOMICS BIOTECH, S.L. ES (BARCELONA) participant 275˙218.00
7    CABALLERO LLANO CARMELO CESAR PY (ASUNCION) participant 216˙093.00
8    EUROPEAN CANCER PATIENT COALITION BE (BRUXELLES) participant 197˙750.00
9    ALEXANDER FLEMING SA AR (BUENOS AIRES) participant 131˙625.00
10    UNIVERSITAET LEIPZIG DE (LEIPZIG) participant 131˙156.00
11    Instituto Nacional de Cancerología MX (MEXICO) participant 0.00

Map

 Project objective

Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America. None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known. From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients. The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEGACY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEGACY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More